Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer

Charles G. Drake, MD, PhD
Published: Friday, Apr 28, 2017



Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Currently, there are 4 immunotherapy agents that have data in bladder cancer: 2 PD-L1 antibodies—atezolizumab (Tecentriq) and durvalumab—and 2 PD-1 antibodies, which are nivolumab (Opdivo) and pembrolizumab (Keytruda).

  Drake says that these 4 drugs look very similar in terms of response rates and adverse events. Some suggest that anti–PD-L1 might be better tolerated, Drake adds, but those opinions are based on cross-trial comparisons.
 
SELECTED
LANGUAGE


Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Currently, there are 4 immunotherapy agents that have data in bladder cancer: 2 PD-L1 antibodies—atezolizumab (Tecentriq) and durvalumab—and 2 PD-1 antibodies, which are nivolumab (Opdivo) and pembrolizumab (Keytruda).

  Drake says that these 4 drugs look very similar in terms of response rates and adverse events. Some suggest that anti–PD-L1 might be better tolerated, Drake adds, but those opinions are based on cross-trial comparisons.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment DataApr 30, 20191.5
Publication Bottom Border
Border Publication
x